Document:

Exhibit 10.25

 

 

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

 

“Agreement Amendment No. 2”

 

[17 March, 2011]

 

Janssen Pharmaceutica N.V.

Turnhoutseweg 30

B-2340 Beerse

Belgium

 

Elan Drug Delivery, Inc.

3500 Horizon Drive

King of Prussia, PA 19046

USA

 

Dear Sirs

 

RE:                            License Agreement dated March 31, 1999 (the “Agreement”), as amended by letter amendment of July 31, 2003, between Elan Drug Delivery, Inc. (successor in interest in and to Elan Pharmaceutical Research Corp., d/b/a Nanosystems(“EDDI”) and Elan Pharma International Limited (“EPIL”)  (EDDI and EPIL collectively hereinafter referred to as “Elan”) and Janssen Pharmaceutica N.V.  (“Janssen”)

 

Elan and Janssen hereby agree that with effect from July 31, 2009 this Agreement Amendment No. 2 (“Agreement Amendment No. 2 Effective Date”) the Agreement shall be amended as follows:

 

1.                                      All references in the Agreement to EPRC shall read EDDI.  All references to NANO shall read Elan.

 

2.                                      Article 22             Elan contact details only - shall be deleted and replaced with the following:

 

If to Elan:                                                                                   Elan Pharma International Limited

 

 

	
 
    	
EPIL Letter to Janssen   and EDDI of 23 July 2009
    
	
 
    	
Amendment No 2 to license   dated 31 March 1999, as amended
    

 

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

 

	
 
    	
Monksland, Athlone, County Westmeath, Ireland
    
	
 
    	
 
    
	
 
    	
Attention:
    	
Vice President & Legal Counsel
    
	
 
    	
Telefax:
    	
00 353 90 64 95402
    
	
 
    	
 
    
	
With a copy to:
    	
Elan Drug Delivery, Inc.
    
	
 
    	
3500 Horizon Drive, King of Prussia, PA 19406,
    
	
 
    	
USA
    	
 
    
	
 
    	
 
    
	
 
    	
Attention:
    	
President
    
	
 
    	
Telefax:
    	
001 610-313-5182
    

 

3.                                      Patent Schedules

 

3.1                               Exhibit A: Nano Patents shall be deleted and replaced with Exhibit A:  Nano Patents — Updated January, 2011, attached hereto.

 

Exhibit B:  Selection Patents shall be deleted and replaced with Exhibit B Selection Patents — Updated January 2011, attached hereto.

 

4.                                      Defined texts used in this Agreement Amendment No. 2 shall have the meaning assigned to them in the Agreement unless such terms are expressly defined in this Agreement Amendment No. 2.  All other provisions of the Agreement not amended herein shall remain unchanged and in full force and effect.

 

	
Yours faithfully,
    	
 
    
	
 
    	
 
    
	
Signed on behalf of:
    	
 
    
	
Elan Pharma International   Limited
    	
 
    
	
 
    	
 
    
	
/s/ William Daniel
    	
 
    
	
Name: 
    	
William Daniel
    	
 
    
	
Title: 
    	
Director
    	
 
    
	
Date: 
    	
1 April 2011
    	
 
    

 

Agreed and accepted for and on behalf of

Elan Drug Delivery, Inc. successor in interest in and to Elan Pharmaceutical Research Corp., d/b/a Nanosystems

 

2

 

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

 

	
 
    	
 
    
	
/s/ David Czekai
    	
 
    
	
Name: David Czekai
    	
 
    
	
Title: VP and GM
    	
 
    
	
Date: 18 Apr 2011
    	
 
    
	
 
    	
 
    
	
Accepted for and on behalf of:
    	
 
    
	
Janssen Pharamceutica   N.V.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Ludo Lauwers
    	
 
    
	
Name: Ludo Lauwers
    	
 
    
	
Title: Senior Vice   President, Site Management
    	
 
    
	
Date: 17 March 2011
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Dirk Collier
    	
 
    
	
Member of the Board
    	
 
    

 

3

 

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

 

Exhibit A: Nano Patents—Updated January, 2011

 

[*****]

 

4

 

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

 

[Exhibit B: Selection Patents—Updated July 31, 2009]

 

[*****]

 

5Exhibit 10.52

 

Execution Version

 

AMENDMENT NO. 3 AND WAIVER TO 
 AMENDED AND RESTATED CREDIT AGREEMENT

 

THIS AMENDMENT NO. 3 AND WAIVER TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) dated as of May 22, 2013 is entered into by and among Alkermes, Inc., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), Alkermes plc, a company incorporated under the laws of the Republic of Ireland (“Holdings”), Alkermes Pharma Ireland Limited, a private limited company organized under the laws of the Republic of Ireland (“Intermediate Holdco”), Alkermes US Holdings, Inc. (“Holdco”), Morgan Stanley Senior Funding, Inc., as administrative agent (in such capacity,  the “Administrative Agent”) and as collateral agent (in such capacity, the “Collateral Agent”), and the undersigned lenders.  Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement (as defined below).

 

PRELIMINARY STATEMENTS:

 

(1)                                 The Borrower, Holdings, Intermediate Holdco, Holdco, the Administrative Agent and Collateral Agent, Morgan Stanley Senior Funding, Inc., Citigroup Global Markets, Inc. and JPMorgan Chase Bank, N.A., as co-syndication agents and the financial institutions from time to time party thereto as term lenders (the “Lenders”) entered into that certain Amended and Restated Credit Agreement, initially dated as of September 16, 2011 and amended and restated on September 25, 2012, as further amended as of February 14, 2013  (the “Credit Agreement”);

 

(2)                                 The Borrower, Holdings, the other Loan Parties party thereto have requested that the Lenders and the Administrative Agent agree to amend the Credit Agreement and grant certain waivers thereunder, and the Lenders and the Administrative Agent have agreed to such amendments and waivers, as hereinafter set forth;

 

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the parties hereto hereby agree as follows:

 

SECTION 1.                            Amendments and Waivers to Credit Agreement.

 

1.1. Amendments

 

The Credit Agreement is, effective as of the date hereof and subject to the satisfaction of the conditions precedent set forth in Section 3, hereby amended as follows:

 

(a)         The definition of “ECF Percentage” appearing in Section 1.1 of the Credit Agreement is hereby amended by deleting “March 31, 2014” appearing therein and substituting in lieu therefor “December 31, 2013”.

 

(b)         The definition of “Excess Cash Flow Payment Period” appearing in Section 1.1 of the Credit Agreement is hereby amended by deleting “March 31, 2014” appearing therein and substituting in lieu therefor “December 31, 2013”.

 

 

(c)          Section 3.2(c) of the Credit Agreement is hereby amended by deleting “March 31, 2014” appearing therein and substituting in lieu therefor “December 31, 2013”.

 

1.2. Waiver

 

The Lenders, effective as of the date hereof and subject to the satisfaction of the conditions precedent set forth in Section 3, hereby waive Section 7.11(a) thereof in order to permit Holdings to change its fiscal year such that it will end on December 31 of each year, commencing with the fiscal year ending on December 31, 2013.

 

SECTION 2.                            Reference to and Effect on the Loan Documents.

 

(a)         On and after the Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to “the Credit Agreement”, “the First-Lien Credit Agreement,” “the Amended and Restated Credit Agreement,” “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as amended by this Amendment.

 

(b)         The Credit Agreement, as specifically amended and waived by this Amendment, and the other Loan Documents are, and shall continue to be, in full force and effect, and are hereby in all respects ratified and confirmed.

 

(c)          Except as expressly provided herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under the Credit Agreement or any other Loan Document, nor shall it constitute a waiver of any provision of the Credit Agreement or any Loan Document.

 

SECTION 3.                            Conditions of Effectiveness.  This Amendment shall become effective as of the date (the “Effective Date”) on which each of the following conditions shall have been satisfied (or waived):

 

(a)         The Administrative Agent shall have received from (i) the Lenders under the Credit Agreement constituting Required Lenders, and (ii) the Administrative Agent, executed counterparts of this Amendment or written evidence reasonably satisfactory to the Administrative Agent that such party has executed this Amendment on, or prior to, 5 p.m., New York City time on May 8, 2013 (the “Consent Deadline”).

 

(b)         The Administrative Agent shall have received from the Loan Parties party hereto, executed counterparts of this Amendment or written evidence reasonably satisfactory to the Administrative Agent that such party has executed this Amendment.

 

(c)          As of the Effective Date, no event shall have occurred and be continuing that would constitute a Default or Event of Default under the Agreement.

 

SECTION 4.                            Costs and Expenses.

 

The Borrower agrees that all reasonable out-of-pocket expenses incurred by the Administrative Agent in connection with the preparation, execution, delivery and administration,

 

2

 

modification and amendment of this Amendment and the other instruments and documents to be delivered hereunder or in connection herewith (including, without limitation, the reasonable fees, charges and disbursements of Shearman & Sterling LLP, counsel for the Administrative Agent), are expenses that the Borrower are required to pay or reimburse pursuant to Section 10.5 of the Credit Agreement.

 

SECTION 5.                            Miscellaneous.

 

(a)         Execution in Counterpart.  This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.  Delivery of an executed counterpart of a signature page to this Amendment by telecopier or other electronic means shall be effective as delivery of a manually executed counterpart of this Amendment.

 

(b)         Binding Effect.  This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

 

(c)          Headings.  The headings listed herein are for convenience only and do not constitute matters to be construed in interpreting this Amendment.

 

(d)         Waiver & Modification.  No provision of this Amendment may be modified, altered or otherwise amended, except by an instrument in writing executed by each of the parties hereto.

 

(e)          GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

 

(f)           WAIVER OF RIGHT OF TRIAL BY JURY.  EACH PARTY TO THIS AMENDMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS AMENDMENT, OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THE CREDIT AGREEMENT AS AMENDED HEREBY, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

3

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective authorized officers as of the date first above written.

 

	
 
    	
BORROWER:
    
	
 
    	
 
    
	
 
    	
ALKERMES, INC., as   Borrower
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ James M.   Frates
    
	
 
    	
 
    	
Name: James M.   Frates
    
	
 
    	
 
    	
Title:   Senior Vice President, Chief Financial   Officer & Treasurer
    

 

Alkermes

May 2013 Amendment and Waiver

 

 

	
GIVEN under the common seal of
    	
 
    
	
ALKERMES PLC, as Holdings
    	
 
    
	
and DELIVERED as a DEED
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Shane Cooke
    	
 
    
	
Director
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Tom Riordan
    	
 
    
	
Assistant   Secretary
    	
 
    

 

Alkermes

May 2013 Amendment and Waiver

 

 

	
 
    	
ALKERMES US HOLDINGS, INC.,   as Holdco
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ James M.   Frates
    
	
 
    	
 
    	
Name: James M.   Frates
    
	
 
    	
 
    	
Title:   VP, CFO and Treasurer
    

 

Alkermes

May 2013 Amendment and Waiver

 

 

	
GIVEN under the common seal of
    	
 
    
	
ALKERMES PHARMA IRELAND   LIMITED,
    	
 
    
	
as Intermediate Holdco
    	
 
    
	
and DELIVERED as a DEED
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Richie Paul
    	
 
    
	
Director
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Tom Riordan
    	
 
    
	
Assistant   Secretary
    	
 
    

 

Alkermes

May 2013 Amendment and Waiver

 

 

	
 
    	
MORGAN STANLEY SENIOR   FUNDING, INC.,
    
	
 
    	
as Administrative Agent,   Collateral Agent and a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Stephen B.   King
    
	
 
    	
 
    	
Name:
    	
Stephen B. King
    
	
 
    	
 
    	
Title:
    	
Vice President
    

 

Alkermes

May 2013 Amendment and Waiver

 

 

	
 
    	
[                              ],
    
	
 
    	
as a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    

 

Alkermes

May 2013 Amendment and Waiver

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]